n.
Skin accidentally exposed to Novantrone should be rinsed copiously with warm water and if the eyes are involved, standard irrigation techniques should be used immediately. The use of goggles, gloves, and protective gowns is recommended during preparation and administration of the drug.
Procedures for proper handling and disposal of anticancer drugs should be considered. Several guidelines on this subject have been published.1-4 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.
REFERENCES
NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.
OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi2.html.
American Society of Health-System Pharmacists. (2006) ASHP Guidelines on Handling Hazardous Drugs.
Polovich, M., White, J.M., & Kelleher, L.O. (eds.) 2005. Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed.) Pittsburgh, PA: Oncology Nursing Society.
How is Novantrone Supplied
Novantrone® (mitoxantrone for injection concentrate) is a sterile aqueous solution containing mitoxantrone hydrochloride at a concentration equivalent to 2 mg mitoxantrone free base per mL supplied in vials for multidose use as follows:
NDC 44087-1520-1 - 20 mg/10 mL/multidose vial (2 mg/mL)
Novantrone® (mitoxantrone for injection concentrate) should be stored between 15°-25°C (59°-77°F). DO NOT FREEZE.
Issue Date: June 2010
Manufactured for: EMD Serono, Inc. Rockland, MA 02370 USA
Marketed by: Marketed by:
(OSI)TM oncology EMD Serono, Inc.
For oncology &nbs
